secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0000950170-22-026736
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences reports promising interim results for HBV core inhibitors 3733 and 4334
--------------------------------------------------------------------------------

- ABI-H3733 50 mg cohort: 6 of 8 HBV patients reached HBV DNA <LLOQ by day 21; mean 3.1 log decline.
- No serious adverse events or significant ALT elevations observed in either study.
- ABI-4334 30 mg single-dose showed 24-hour half-life supporting once-daily oral dosing; PK suggests high potency.
- 100 mg cohorts ongoing for both studies; further data expected in Q1 2023.
- ABI-H3733 25 mg cohort enrolled; initial 5 patients showed mean HBV DNA reduction of ~1.9 logs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017022026736/0000950170-22-026736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017022026736/asmb-20221219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer